ClinicalTrials.gg
TerminatedNCT04868877Updated Oct 26, 2026

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

A Phase 1/2 interventional study of MCLA-129 and Osimertinib in Non-Small Cell Lung Cancer Metastatic, Gastric Cancer and Esophageal Squamous Cell Carcinoma, sponsored by Merus B.V.. Terminated at 51 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Merus B.V. (part of Genmab) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.
Updated Oct 26, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
194
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 173 studies in Stomach Neoplasms with a site in Spain — 37 open to participants now, 63 under way, 12 of them phase 3. Stomach Neoplasms · Spain.

Enrollment
69th of 148
194 · median 174
Started
2021
with 11 others
Phase 1/2
23 of 173
6 open now
Registered
111th of 173
by date

Among the 173 studies in Stomach Neoplasms with a site in Spain, this one is the 69th largest by enrollment of the 148 interventional ones that give a count, is one of 12 that started in 2021, is one of 23 in phase 1/2, and was the 111th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

37 of the 173 studies in Stomach Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Stomach Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.

03

Conditions studied

  • Non-Small Cell Lung Cancer Metastatic
  • Gastric Cancer
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Colorectal Cancer

Keywords

  • MCLA-129
  • EGFR inhibitor
  • NSCLC
  • C-MET
  • GC/GEJ
  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part One: Patients with NSCLC, GC/GEJ, HNSCC, or ESCC who have failed prior standard treatment. Patients must have progressed on or be intolerant to therapies that are known to provide clinical benefit. There is no limit to the number of prior treatment regimens.

Part Two: Patients with NSCLC, HNSCC, other solid tumors and applicable mutations as determined by the investigator.

  • Availability of archival or a fresh tumor tissue sample.
  • as defined by version 1.1 by radiologic methods.
  • (ECOG) performance status of 0 or 1.
  • ≥ 12 weeks, as per Investigator.
  • Adequate organ function (as per protocol)

Exclusion Criteria:

  • Central nervous system that are untreated or symptomatic, or require radiation, surgery, or continued therapy (> 10 mg prednisone or equivalent) to control symptoms within 14 days of study entry.
  • Known .
  • Participation in another clinical study or treatment with any drug within 4 weeks prior to study entry.
  • Systemic anticancer therapy or immunotherapy within 4 weeks or 5 half-lives, whichever is shorter, of the first dose of study drug. For cytotoxic agents that have major delayed toxicity (e.g., mitomycin C, nitrosoureas), a of 6 weeks is required.
  • Major surgery or radiotherapy within 3 weeks of the first dose of study drug. Patients who received prior radiotherapy to ≥25% of bone marrow at any time are not eligible.
  • Persistent grade >1 toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 v5.0 and hypothyroidism ≤ grade 2 which is stable on hormone replacement are allowed.
  • History of reaction or any toxicity attributed to human proteins or any of the that warranted permanent cessation of these agents. History of hypersensitivity reaction or any toxicity attributed to chemotherapy and components.
  • History of clinically significant cardiovascular disease
  • Past medical history of ILD or pneumonitis, or any evidence of clinically active ILD or pneumonitis.
  • Previous or concurrent , excluding non-basal cell carcinomas of skin or carcinoma in situ of the uterine cervix, unless the tumor was treated with curative or palliative intent and in the opinion of the Investigator, with Sponsor agreement, the previous or concurrent malignancy condition does not affect the assessment of safety and efficacy of the study drug.
  • Current serious illness or medical conditions including, but not limited to uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
  • Active infection without receiving antiviral treatment.
  • Positive test for
  • Known history of (HIV 1/2 antibodies). Patients with HIV with undetectable viral load are allowed. In
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Part 2 NSCLC Second-line or more harboring EGFR exon 20 Insertion

    Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).

    Drug: MCLA-129

  • Experimental
    Part 2 NSCLC Second-line or more harboring cMet exon 14 skipping mutation

    Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).

    Drug: MCLA-129

  • Experimental
    Part 2 Selected solid tumors with or without an EGFR or cMet alteration

    Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).

    Drug: MCLA-129

  • Experimental
    Part 2 NSCLC First-line harboring EGFR sensitizing mutations

    Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.

    Drug: MCLA-129 · Drug: Osimertinib

  • Experimental
    Part 2 NSCLC Second-line or more, osimertinib resistant (combo with osimertinib)

    Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.

    Drug: MCLA-129 · Drug: Osimertinib

  • Experimental
    Part 2 NSCLC Second-line or more, osimertinib resistant (combo with chemotherapy)

    Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and chemotherapy every three weeks per standard of care according to local guidance.

    Drug: MCLA-129 · Drug: Chemotherapy

  • Experimental
    Part 2 NSCLC Third-line or more, osimertinib resistant, platinum resistant (combo with chemotherapy)

    Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and chemotherapy every three weeks per standard of care according to local guidance.

    Drug: MCLA-129 · Drug: Chemotherapy

Interventions

  • full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

    Also known as: bispecific

  • Approved, 3rd-generation EGFR-TKI

    Also known as: Tagrisso

  • DrugChemotherapy

    administrated by IV infusion

06

What researchers measure

Primary outcomes

  1. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)

    To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-129 as well as in combination with chemotherapy in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for advanced/metastatic disease.

    Time frame: First 28 days of treatment

  2. To evaluate clinical activity, as assessed by ORR

    To evaluate the ORR of MCLA-129 monotherapy or in combination with an EGFR TKI or chemotherapy in molecularly defined populations of advanced/metastatic solid tumors.

    Time frame: From first dose until RECIST progression or initiation of an alternative treatment, whichever occurs first.

Secondary outcomes

  1. To evaluate preliminary antitumor activity in terms of BOR

    To evaluate preliminary antitumor activity of MCLA-129 monotherapy as well as in combination with an EGFR TKI or chemotherapy in terms of best overall response (BOR)

    Time frame: From first dose until RECIST progression or initiation of an alternative treatment, whichever occurs first.

  2. To evaluate preliminary antitumor activity in terms of DCR

    To evaluate preliminary antitumor activity of single-agent MCLA-129 as well as in combination with an EGFR TKI or with chemotherapy in terms of Disease Control Rate (DCR).

    Time frame: From first dose until RECIST progression or initiation of an alternative treatment, whichever occurs first.

  3. To evaluate preliminary antitumor activity in terms of DoR

    To evaluate preliminary antitumor activity of single-agent MCLA-129 as well as in combination with an EGFR TKI or with chemotherapy in terms of Duration of Response (DoR)

    Time frame: From first dose until RECIST progression or initiation of an alternative treatment, whichever occurs first.

  4. To evaluate progression-free survival (PFS)

    To evaluate progression-free survival (PFS) of single-agent MCLA-129 as well as in combination with an EGFR TKI or with chemotherapy.

    Time frame: From first dose until RECIST progression or until 1 year after treatment, whichever occurs first.

  5. To evaluate overall survival (OS)

    To evaluate overall survival (OS) of single-agent MCLA-129 as well as in combination with an EGFR TKI or with chemotherapy.

    Time frame: From first dose until RECIST progression or until 1 year after treatment, whichever occurs first.

  6. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 of single-agent MCLA-129 as well as in combination with an EGFR TKI or with chemotherapy

    Time frame: From first dose until study treatment discontinuation

  7. Proportion of patient with treatment discontinuations of single-agent MCLA-129 as well as in combination with an EGFR TKI or with chemotherapy.

    Time frame: From first dose until study treatment discontinuation

  8. AE, regardless of relationship to study treatment

    Time frame: From first dose until study treatment discontinuation

  9. All safety endpoints

    including vital sign, lab, ECG, ECHO, 4 weeks CT scan, Eye exam

    Time frame: From first dose until study treatment discontinuation

07

Study locations

51 sites
  • University of California, Irvine
    Orange, California 92868, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • START Mountain Region
    West Valley City, Utah 84119, United States
  • Next Oncology Virginia
    Fairfax, Virginia 22031, United States
  • Institut Jules Bordet
    Anderlecht, Belgium
  • Antwerp University Hospital
    Edegem, 2650, Belgium
  • Clinique de l'Europe
    Amiens, 80090, France
  • CHU Hopitaux de Bordeaux - Hôpital Saint-André
    Bordeaux, 33000, France
  • CHU de Lyon - Louis Pradel Hospital
    Bron, 69677, France
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, 94010, France
  • Hôpital Albert Calmette
    Lille, 59037, France
  • L'Institut Paoli - Calmettes
    Marseille, 13009, France
  • CHU de Nantes - Hôpital Nord Laennec
    Nantes, 44093, France
  • Marie Wislez
    Paris, 75014, France
  • Hôpital Bichat - Claude-Bernard
    Paris, 75877, France
  • Hôpital Européen Georges Pompidou (HEGP)
    Paris, 75908, France
  • CHU de Poitiers
    Poitiers, 86000, France
  • Hôpital d'Instruction des Armées Bégin
    Saint-Mandé, 94163, France
  • Krankenhaus Nordwest
    Frankfurt am Main, Hesse 60488, Germany
  • Sana Klinikum Offenbach GmbH
    Offenbach, 63069, Germany
  • Istituto Nazionale dei Tumori Regina Elena
    Roma, Rome 00144, Italy
  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • ASST degli Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, 22162, Italy
  • Azienda Ospedaliero - Universitaria San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona
    Salerno, 84131, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
    Verona, 37126, Italy
  • Netherlands Cancer Institute
    Amsterdam, Netherlands
  • University Medical Center Groningen
    Groningen, Netherlands
  • Erasmus Medical Center
    Rotterdam, Netherlands
  • National Cancer Centre of Singapore
    Singapore, 169610, Singapore
  • Gachon University Gil Hospital
    Incheon, 21565, South Korea
  • Samsung Medical Center
    Seoul, 6351, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Severance Hospital - Yonsei Cancer Center
    Seoul, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, South Korea
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Gyeonggi-do, 16247, South Korea
  • Hospital HM Delfos
    Barcelona, 08023, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • IOB Institute of Oncology - Hospital Quironsalud Barcelona
    Barcelona, 8023, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Clínica Universidad de Navarra -Madrid
    Madrid, 28027, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Centro Integral Oncológico Clara Campal
    Madrid, 28050, Spain
  • Hospital Quirón Madrid
    Madrid, 28223, Spain
  • Clínica Universidad de Navarra
    Pamplona, 31008, Spain
  • Fundación Instituto Valenciano de Oncología (IVO)
    Valencia, 46009, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2021 to primary completion in Oct 2026, 65 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2026 → Oct 2026 and completion Mar 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
May 3, 2021
StartActual
Apr 28, 2021
Primary completionActual
Oct 1, 2026was Mar 2026
CompletionActual
Oct 1, 2026was Mar 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.
changed Oct 26, 2026
Primary completion
Mar 2026→Oct 1, 2026 (actual)
Oct 26, 2026
Study completion
Mar 2027→Oct 1, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Active, not recruiting→Terminated
    Why stopped The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.
    Primary completion Mar 2026→Oct 1, 2026 (now actual)
    Study completion Mar 2027→Oct 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04868877
Lead sponsor
Merus B.V.
Responsible party
Sponsor
First posted
May 3, 2021
Start date
Apr 28, 2021
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pamvatamig

Start the discussion